Evaluation of the Efficacy of Hippotherapy for Children With Developmental Disorders

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Dr. Lidia Gabis MD, Sheba Medical Center
ClinicalTrials.gov Identifier:
NCT00717392
First received: July 16, 2008
Last updated: February 28, 2013
Last verified: February 2013
  Purpose

Hippotherapy is every program of horseback riding meant to treat people with physiological, mental, social, cognitive or behavioral problems. The purpose of the current research is to evaluate the efficacy of hippotherapy for children with developmental disabilities. The hypothesis is that children with developmental disabilities who are treated with hippotherapy will show better outcomes than children with the same problems who are not treated with hippotherapy.


Condition
Attention Deficit Hyperactivity Disorder
Autism Spectrum Disorder

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Evaluation of the Efficacy of Hippotherapy for Children With Developmental Disorders

Resource links provided by NLM:


Further study details as provided by Sheba Medical Center:

Primary Outcome Measures:
  • Improving the parameters of autism [ Time Frame: Repetitive behaviors ] [ Designated as safety issue: No ]
    Repetitive behaviors Eye contact Communication


Enrollment: 40
Study Start Date: September 2008
Study Completion Date: July 2012
Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts
Hippotherapy_ADHD
10 children with ADHD who receive hippotherapy
Hippotherapy_ASD
10 children with ASD who receive hippotherapy
Control_ADHD
10 children with ADHD who DO NOT receive hippotherapy
Control_ASD
10 children with ASD who DO NOT receive hippotherapy

Detailed Description:

Hippotherapy is every program of horseback riding meant to treat people with physiological, mental, social, cognitive or behavioral problems. Most studies that tested hippotherapy were uncontrolled and focused on motor problems, such as cerebral palsy. Today, hippotherapy is used for various developmental problems such as Attention deficit / Hyperactivity disorder (ADHD) and Autism spectrum disorder (ASD), without clear information about its efficacy for these populations.

The purpose of the current research is to evaluate the efficacy of 6 months of hippotherapy for children with developmental disabilities. The hypothesis is that children with developmental disabilities who are treated with hippotherapy for 6 months will show better outcomes than children with the same problems who are not treated with hippotherapy.

Assessment:

  • BRIEF questionnaire
  • Stony Brook Questionnaire

All questionnaires will be applied at the beginning of the study and after 6 months.

  Eligibility

Ages Eligible for Study:   5 Years to 17 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Hippotherapy subjects will be taken from horseback riding farms. Control subjects will be taken from a tertiary care clinic.

Criteria

Inclusion Criteria:

  • Age: 5-17 years.
  • A diagnosis of ADHD or ASD.

Exclusion Criteria:

  • None.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00717392

Locations
Israel
Weinberg Child Development Center, Sheba Medical Center, Tel-Hashomer
Ramat-Gan, Israel
Sponsors and Collaborators
Sheba Medical Center
Investigators
Principal Investigator: Lidia Gabis, MD Sheba Medical Center
  More Information

No publications provided

Responsible Party: Dr. Lidia Gabis MD, Director, The Weinberg Child Development Center, Sheba Medical Center
ClinicalTrials.gov Identifier: NCT00717392     History of Changes
Other Study ID Numbers: SHEBA-08-5327-LG-CTIL
Study First Received: July 16, 2008
Last Updated: February 28, 2013
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Keywords provided by Sheba Medical Center:
ADHD
ASD

Additional relevant MeSH terms:
Disease
Hyperkinesis
Attention Deficit Disorder with Hyperactivity
Child Development Disorders, Pervasive
Developmental Disabilities
Pathologic Processes
Dyskinesias
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Attention Deficit and Disruptive Behavior Disorders
Mental Disorders Diagnosed in Childhood
Mental Disorders

ClinicalTrials.gov processed this record on September 30, 2014